sinc
februari
confirm
case
human
infect
novel
avian
influenza
viru
continu
identifi
china
novemb
total
confirm
case
report
includ
death
first
time
avian
influenza
viru
infect
report
human
viru
identifi
novel
reassort
influenza
viru
differ
genet
previous
identifi
avian
influenza
virus
carri
six
intern
gene
origin
avian
influenza
virus
hemagglutinin
ha
neuraminidas
na
gene
avian
influenza
virus
respect
investig
viral
sequenc
reveal
viru
contain
sever
mammalianadapt
mutat
known
associ
improv
invas
replic
avian
influenza
virus
mammal
subsequ
experiment
studi
demonstr
viru
could
replic
respiratori
tract
variou
anim
includ
nonhuman
primat
could
transmit
direct
contact
aerosol
ferret
addit
demonstr
infect
chicken
could
surviv
shed
viru
day
without
obviou
clinic
sign
diseas
observ
low
pathogen
avian
influenza
viru
poultri
weaken
warn
effect
symptombas
screen
infect
poultri
thu
facilit
spread
viru
among
poultri
increas
risk
human
exposur
although
sustain
humantohuman
transmiss
determin
sever
case
famili
cluster
identifi
provinc
china
experienc
outbreak
suggest
limit
nonsustain
humantohuman
transmiss
may
occur
circumst
longterm
unprotect
close
contact
consid
probabl
lack
preexist
immun
among
human
newli
emerg
viru
viru
pose
great
threat
nation
global
public
health
laboratorydesign
inhous
nucleotid
detect
assay
develop
use
public
health
laboratori
chines
nation
influenzalik
ill
surveil
network
cnisn
assay
current
main
tool
employ
rapid
identif
avian
influenza
viru
play
critic
role
earli
respons
outbreak
avian
viru
infect
howev
possibl
sustain
humantohuman
transmiss
complet
exclud
new
case
continu
accumul
appear
second
epidem
wave
winter
spring
china
care
persist
monitor
avian
influenza
viru
necessari
urgent
longterm
respons
threat
viru
thu
enhanc
detect
capac
sustain
qualitycontrol
measur
urgent
need
allow
better
respons
current
outbreak
novel
influenza
viru
improv
prepared
reemerg
even
potenti
pandem
futur
compar
inhous
assay
commerci
diagnost
kit
typic
provid
sustain
altern
sourc
accur
detect
test
support
largerscal
product
certifi
manufactur
practic
wellstudi
product
perform
stabl
qualiti
control
henc
use
broad
rang
clinic
laboratori
therefor
meet
increas
need
detect
china
food
drug
administr
cfda
approv
three
commerci
diagnost
product
specif
detect
avian
influenza
viru
rna
use
laboratori
part
cnisn
emerg
use
author
eua
ensur
safeti
effect
commerci
molecular
diagnost
assay
conduct
analyt
clinic
evalu
use
wellcharacter
qualitycontrol
panel
viral
cultur
suffici
number
clinic
specimen
collect
throughout
major
epidem
region
china
studi
protocol
inform
consent
document
review
approv
ethic
committe
first
affili
hospit
colleg
medicin
zhejiang
univers
zju
hospit
shanghai
public
clinic
health
center
sphcc
nanj
municip
center
diseas
control
prevent
nanj
cdc
zhejiang
provinci
center
diseas
control
prevent
zhejiang
cdc
guangdong
provinci
center
diseas
control
prevent
guangdong
cdc
guangzhou
municip
center
diseas
control
prevent
guangzhou
cdc
jiangsu
provinci
center
diseas
control
prevent
jiangsu
cdc
written
inform
consent
research
use
clinic
sampl
obtain
patient
involv
studi
five
strain
avian
influenza
viru
viru
isol
cultur
laboratori
establish
qualitycontrol
panel
briefli
throatswab
specimen
obtain
patient
maintain
viraltransport
medium
viru
strain
obtain
propag
clinic
specimen
allanto
sac
amniot
caviti
specif
pathogenfre
embryon
chicken
egg
h
viru
titer
ha
titer
determin
accord
protocol
recommend
cultur
supernat
two
viru
strain
prepar
state
key
laboratori
diagnosi
treatment
infecti
diseas
colleg
medicin
zhejiang
univers
china
viral
titer
respect
three
strain
cultur
nation
institut
viral
diseas
control
prevent
part
chines
center
diseas
control
prevent
collabor
center
refer
research
influenza
cc
titer
virus
ha
unit
ha
unit
ha
viral
cultur
five
virus
inactiv
betapropriolacton
inactiv
statu
confirm
viral
cultur
prior
use
laboratori
establish
qualitycontrol
panel
subsequ
evalu
commerci
assay
twelv
influenza
viru
strain
also
isol
identifi
cultur
cnic
base
standard
oper
procedur
includ
influenza
season
isol
pandem
influenza
b
virus
tabl
harvest
suffici
amount
viral
cultur
supernat
immedi
frozen
use
viral
cultur
supernat
confirm
rtpcr
sequenc
accord
protocol
recommend
cnic
file
cultur
supernat
viru
test
follow
pcr
sequenc
primer
ggcaacaggaatgaagaatgttcc
cacygcatgtttccattctt
segment
gtgattcagatagacccagtagca
actccagtcagcgtttaatacaat
segment
sequenc
result
align
influenza
sequenc
deposit
global
initi
share
avian
influenza
data
gisaid
databas
http
platformgisaidorg
influenza
research
databas
ird
http
wwwfludborg
identifi
correct
type
subtyp
virus
rtpcr
sequenc
analys
independ
perform
use
ident
protocol
two
differ
laboratori
nation
institut
food
drug
control
nifdc
beij
institut
radiat
medicin
birm
process
dilut
dispens
viral
cultur
conduct
biosaf
protect
environ
freezedri
conduct
gmp
grade
environ
multipett
stream
electron
hand
dispens
combitip
biosaf
tip
eppendorf
germani
use
dispens
process
approxim
ml
viral
cultur
supernat
viru
strain
design
respect
directli
dispens
aliquot
screwcap
tube
cultur
supernat
remain
three
virus
design
respect
dilut
lysi
buffer
rlt
qiagen
germani
mix
min
room
temperatur
gener
three
bulk
sampl
bulk
sampl
dispens
aliquot
screwcap
tube
liquid
aliquot
viru
store
cultur
supernat
influenza
viru
strain
dilut
lyophil
buffer
gener
bulk
sampl
bulk
sampl
ml
place
penicillin
bottl
immedi
process
lyophil
avoid
crosscontamin
penicillin
bottl
fill
differ
type
subtyp
viru
freezedri
accord
routin
procedur
separ
day
penicillin
bottl
lightli
fit
rubber
stopper
lyophil
genesi
freezedry
virti
usa
final
penicillin
bottl
crimpseal
aluminum
ring
store
procedur
paramet
typic
freezedri
process
shown
file
complet
dna
sequenc
three
viral
segment
ha
segment
viru
strain
gisaid
access
number
mp
segment
influenza
viru
strain
genbank
access
number
ns
segment
influenza
b
viru
strain
genbank
access
number
commerci
synthes
puc
pbluescriptderiv
plasmid
vector
takara
biotech
dalian
china
sequenc
synthet
ha
mp
ns
fragment
verifi
laboratori
pcr
sequenc
use
plasmidspecif
primer
reduc
plasmid
background
pcr
product
promot
sequenc
use
templat
subsequ
vitro
transcript
use
construct
plasmid
templat
pcr
essenti
sequenc
promot
ad
upstream
ha
mp
ns
fragment
use
specif
primer
tabl
next
pcr
product
gelextract
photometr
quantifi
transcrib
rna
use
megascript
vitro
transcript
kit
ambion
life
technolog
usa
rnasefre
dnase
digest
rna
transcript
purifi
use
qiagen
rneasi
kit
qiagen
germani
quantifi
photometr
nanodrop
thermo
usa
copi
number
vitro
rna
transcript
calcul
accord
follow
formula
rna
quantiti
rna
concentr
rna
length
nt
tenfold
serial
dilut
rna
transcript
use
gener
standard
curv
quantif
qualitycontrol
panel
base
whorecommend
realtim
rtpcr
method
realtim
stabil
evalu
conduct
month
panel
produc
panel
sampl
extract
test
two
independ
experi
use
inhous
assay
monitor
increas
threshold
cycl
ct
valu
compar
valu
time
product
month
accelerateddegrad
studi
also
conduct
evalu
stabil
qualitycontrol
panel
panel
sampl
place
week
repeatedli
freezethaw
five
time
treatment
sampl
refrozen
test
concurr
untreat
sampl
store
two
independ
experi
use
cnic
realtim
rtpcr
method
differ
ct
valu
untreat
treat
sampl
analyz
commerci
kit
evalu
studi
produc
shanghai
zj
biotech
co
ltd
liferiv
daan
gene
co
ltd
sun
yatsen
univers
daan
shenzhen
puruikang
biotech
co
ltd
puruikang
randomli
sampl
three
success
produc
lot
assay
blind
manufactur
evalu
kitrel
inform
provid
manufactur
summar
tabl
rna
extract
reagent
recommend
manufactur
use
accord
instruct
provid
kit
specif
liferiv
daan
assay
rna
extract
reagent
nucleic
acid
isol
kit
spin
column
method
produc
kit
manufactur
puruikang
assay
tianamp
viru
rna
kit
spin
column
method
produc
tiangen
biotech
beij
co
ltd
rna
extract
process
three
commerci
assay
conduct
manual
whocnic
assay
rna
extract
perform
use
qiaamp
viral
rna
kit
qiagen
germani
accord
manufactur
protocol
realtim
rtpcr
procedur
result
interpret
commerci
whocnic
assay
conduct
strictli
accord
kit
instruct
protocol
respect
two
modif
analyt
evalu
kit
suspici
result
consid
posit
without
repeat
test
eg
whocnic
assay
posit
result
defin
ct
valu
ct
valu
without
repeat
test
neg
result
defin
reaction
amplif
curv
criteria
intern
control
human
rnasep
consid
interpret
result
analyt
evalu
puruikang
assay
sampl
chicken
egg
allanto
fluid
contain
detect
human
materi
experiment
procedur
result
interpret
qualitycontrol
criteria
kit
document
detail
file
sampl
qualitycontrol
panel
test
use
select
assay
entir
process
rna
extract
amplif
signal
detect
accord
instruct
associ
assay
file
use
neg
sampl
recov
use
rnasefre
pcrgrade
equal
water
determin
analyt
sensit
commerci
kit
whocnic
assay
dilut
prepar
individu
gener
seri
work
sampl
rna
sampl
specif
dilut
pool
sever
extract
test
time
run
determin
limit
detect
lod
defin
least
posit
result
among
replic
probabl
aliquot
dilut
tube
individu
rna
extract
amplif
signal
detect
coeffici
variat
cv
ct
valu
sampl
calcul
everi
product
lot
addit
dilut
factor
prior
use
viral
lysi
buffer
individu
rna
extract
kit
associ
assay
use
dilut
total
virusposit
andneg
sampl
collect
patient
admit
six
hospit
public
health
facil
zju
hospit
nanj
cdc
sphcc
zhejiang
cdc
guangdong
cdc
guangzhou
cdc
februari
may
number
percentag
admit
patient
describ
base
collect
locat
epidem
interv
respect
fig
exclud
patient
whose
age
gender
unspecifi
ili
patient
averag
age
patient
year
rang
day
year
malefemal
ratio
posit
sampl
collect
patient
age
year
rang
year
malefemal
ratio
includ
throat
swab
sputum
specimen
viru
neg
sampl
includ
influenza
virusposit
sampl
subtyp
type
b
influenza
virusposit
sampl
unknown
subtyp
measl
virusposit
sampl
mycobacterium
tuberculosisposit
sampl
mycoplasmaposit
sampl
chlamydia
pneumoniaeposit
sampl
total
virusposit
andneg
sampl
collect
patient
admit
four
hospit
public
health
facil
nanj
cdc
sphcc
zhejiang
cdc
jiangsu
cdc
februari
may
within
first
epidem
period
patient
case
collect
locat
indic
fig
exclud
patient
whose
age
gender
unspecifi
ili
patient
averag
age
patient
year
rang
day
year
malefemal
ratio
one
hundr
twentytwo
posit
sampl
collect
use
throat
swab
patient
age
year
rang
year
malefemal
ratio
viru
neg
sampl
includ
influenza
virusposit
sampl
subtyp
type
b
parainfluenza
virusposit
sampl
respiratori
syncyti
virusposit
sampl
small
rna
virusposit
sampl
adenovirusposit
sampl
bocavirusposit
sampl
human
coronavirusposit
sampl
total
virusposit
andneg
sampl
collect
patient
admit
three
hospit
public
health
facil
zju
hospit
hangzhou
cdc
sphcc
guangdong
cdc
februari
may
number
percentag
admit
patient
describ
base
collect
locat
epidem
interv
respect
fig
two
hundr
ninetyfour
posit
sampl
collect
patient
confirm
viru
infect
includ
throat
swab
sputum
specimen
tracheal
aspir
viru
neg
sampl
includ
throat
swab
sputum
specimen
analysi
varianc
anova
ttest
perform
use
prism
graphpad
softwar
usa
statist
signific
defin
p
posit
neg
agreement
relat
confid
interv
ci
calcul
use
medcalc
medcalc
softwar
bvba
belgium
analyt
evalu
commerci
assay
panel
qualitycontrol
materi
consist
five
posit
twelv
neg
sampl
establish
underw
process
dilut
dispens
freezedri
quantifi
evalu
stabil
set
sampl
produc
total
five
differ
viru
strain
use
evalu
analyt
sensit
reproduc
detect
perform
kit
divers
posit
sampl
base
modifi
realtim
rtpcr
method
standard
curv
rna
copi
number
determin
respect
respect
addit
twelv
neg
sampl
posit
influenza
virus
use
evalu
analyt
specif
assay
sampl
includ
influenza
season
influenza
b
virus
tabl
viru
strain
name
rna
copi
number
sampl
shown
tabl
quantifi
use
modifi
realtim
rtpcr
techniqu
standard
curv
target
mp
gene
influenza
viru
ns
gene
influenza
b
viru
due
rel
larg
amount
bulk
solut
ml
requir
freezedri
method
limit
amount
viral
cultur
obtain
sampl
prepar
liquid
sampl
lyophil
least
set
qualitycontrol
panel
produc
ensur
consist
evalu
meet
longterm
requir
qualiti
control
assay
stabil
studi
indic
sampl
constitut
panel
stabl
even
store
degrad
condit
week
could
repeatedli
freezethaw
five
time
fig
stabl
least
month
fig
packag
compon
appear
panel
illustr
fig
characterist
three
diagnost
assay
list
tabl
appear
kit
shown
fig
addit
principl
basic
reaction
condit
realtim
rtpcr
specif
commerci
assay
illustr
fig
assay
qualit
base
onestep
realtim
rtpcr
method
two
assay
daan
puruikang
duplex
one
assay
liferiv
triplex
taqman
hydrolysi
probe
util
realtim
rtpcr
liferiv
daan
assay
previous
develop
complexprob
techniqu
use
puruikang
assay
unlik
hydrolysi
probe
singl
short
dna
strand
label
report
quencher
end
respect
complex
probe
compos
two
short
dna
strand
label
report
quencher
end
individu
ideal
target
templat
sampl
two
dna
strand
hybrid
form
tight
complex
anneal
extens
thermal
step
thu
fluoresc
emit
individu
kit
show
differ
equip
compat
shown
tabl
howev
abi
realtim
pcr
machin
support
assay
henc
use
evalu
two
assay
daan
liferiv
target
sequenc
viru
exogen
ad
intern
control
simultan
amplifi
use
one
pair
primer
sequenc
probe
target
intern
control
differ
one
use
sampl
posit
control
liferiv
puruikang
assay
pseudoviru
bacteriophag
thu
requir
extract
prior
conduct
realtim
rtpcr
analyt
sensit
result
commerci
whocnic
assay
shown
tabl
target
lod
three
commerci
assay
base
result
replic
dilut
sampl
whocnic
assay
show
better
lod
target
lod
commerci
kit
howev
whocnic
assay
show
higher
frequenc
posit
replic
compar
liferiv
puruikang
assay
interestingli
commerci
assay
show
equal
lod
target
viru
lod
whocnic
assay
unequ
sampl
test
posit
cv
ct
valu
sampl
less
lot
three
test
diagnost
assay
indic
tabl
obviou
differ
within
betweenlot
reproduc
differ
detect
target
commerci
assay
howev
betweenlot
cv
ct
valu
whocnic
assay
higher
valu
obtain
use
commerci
kit
rang
sampl
dilut
correctli
detect
posit
indic
commerci
assay
abil
identifi
divers
virus
result
dilut
sampl
show
statist
signific
differ
ct
valu
target
tabl
addit
sampl
correctli
detect
neg
commerci
kit
indic
crossreact
season
influenza
b
virus
test
lysi
buffer
use
dilut
produc
neg
result
result
three
clinic
trial
shown
tabl
among
clinic
sampl
determin
posit
use
whocnic
assay
also
found
posit
use
liferiv
assay
known
neg
sampl
correctli
identifi
neg
thu
posit
neg
agreement
valu
respect
daan
assay
posit
neg
agreement
valu
respect
respect
result
whocnic
assay
six
posit
sampl
result
discord
daan
assay
refer
assay
throatswab
sampl
subject
rtpcr
sequenc
confirm
among
discord
sampl
three
show
neg
result
rtpcr
sequenc
analysi
indic
extrem
small
amount
target
rna
sampl
posit
neg
agreement
puruikang
assay
influenza
viru
singl
negativestrand
rna
viru
belong
orthomyxovirida
commonli
caus
mild
flu
symptom
also
caus
pneumonia
even
case
acut
respiratori
distress
syndrom
ard
multiorgan
failur
due
frequent
sequenc
alter
segment
exchang
viru
respons
sever
pandem
outbreak
past
centuri
includ
pandem
pandem
recent
pandem
outbreak
china
februari
human
infect
novel
viru
first
report
china
unlik
previou
epidem
avian
influenza
viru
anim
infect
viru
overlook
due
low
pathogen
poultri
earli
stage
outbreak
thu
prevent
control
result
diseas
difficult
importantli
evid
due
reemerg
china
end
viru
continu
evolv
higher
adapt
pathogen
human
increas
possibl
pandem
thu
rapid
sensit
tool
detect
viru
urgent
need
viral
isol
cultur
method
lack
sensit
timeconsum
thu
lead
diagnost
delay
rapid
test
viral
antigen
also
low
sensit
difficult
develop
quickli
due
requir
virusspecif
antibodi
product
addit
detect
specif
antibodi
infect
patient
use
techniqu
enzymelink
immunosorb
assay
elisa
suitabl
earli
diagnosi
diseas
antibodi
requir
week
emerg
howev
molecular
assay
base
realtim
pcr
suitabl
diagnost
surveil
tool
develop
urgent
need
control
current
outbreak
prevent
spread
deleteri
viru
respond
urgent
manner
emerg
prepar
potenti
pandem
novel
influenza
viru
futur
cfda
approv
three
commerci
realtim
rtpcr
assay
specif
detect
avian
influenza
viral
rna
may
juli
emerg
use
addit
februari
us
fda
issu
emerg
use
author
molecular
assay
specif
detect
avian
influenza
viru
diagnost
assay
use
healthcar
facil
effect
assay
must
well
evalu
plasmid
dna
cdna
stabl
materi
wide
use
analyt
evalu
suitabl
assay
use
detect
rna
sampl
revers
transcript
step
character
vitrotranscrib
rna
commonli
use
materi
evalu
perform
rna
detect
assay
howev
use
valid
rna
extract
process
assay
simul
detect
process
clinic
specimen
compon
qualitycontrol
panel
establish
present
studi
produc
inactiv
cultur
supernat
viral
strain
rna
extract
step
could
test
furthermor
biolog
molecular
featur
panel
sampl
viru
titer
copi
number
gene
sequenc
well
character
panel
also
valid
suffici
stabl
longterm
qualitycontrol
requir
use
newli
establish
qualitycontrol
panel
three
commerci
diagnost
product
evalu
analyt
perform
term
sensit
specif
reproduc
inclus
divers
posit
sampl
sequenc
divers
among
virus
isol
differ
patient
observ
previou
studi
thu
abil
identifi
differ
virus
import
factor
qualiti
diagnost
assay
five
differ
virus
panel
addit
posit
clinic
specimen
collect
infect
patient
could
success
detect
thu
valid
sensit
inclus
assay
addit
common
influenza
season
influenza
b
virus
human
test
evalu
specif
product
season
influenza
b
viru
sever
strain
includ
isol
differ
locat
epidem
period
thu
repres
divers
circul
virus
due
similar
sever
symptom
two
strain
anoth
avian
influenza
viru
also
includ
neg
panel
sampl
excel
neg
agreement
refer
whocnic
assay
achiev
neg
panel
sampl
commerci
assay
clinic
neg
sampl
ili
patient
commerci
assay
comparison
whocnic
assay
lower
valu
obtain
cv
within
lot
assay
suggest
evalu
diagnost
assay
reproduc
reliabl
detect
avian
influenza
viru
avian
influenza
viru
consid
replic
preferenti
lower
respiratori
tract
mucos
cell
due
presenc
numer
sialic
acid
receptor
consequ
upper
respiratori
tract
specimen
may
contain
suffici
viral
load
detect
even
peak
infect
rapid
clinic
deterior
limit
number
viral
particl
collect
clinic
sampl
requir
suitabl
sensit
molecular
detect
assay
clinic
set
unfortun
recent
studi
report
evalu
commerci
assay
current
use
frontlin
laboratori
lod
valu
higher
indic
consist
less
sensit
inhous
realtim
rtpcr
assay
furthermor
commerci
multiplex
xtagrvp
assay
luminex
molecular
diagnost
usa
approxim
less
sensit
whocnic
method
differ
may
due
relianc
commerci
assay
detect
conserv
region
segment
influenza
viru
without
optim
detect
novel
viru
harbor
nucleic
acid
variat
within
conserv
region
howev
result
studi
show
commerci
assay
lod
detect
novel
avian
viru
lod
gener
compar
refer
method
whocnic
assay
although
commerci
assay
slightli
less
sensit
refer
method
detect
target
result
obtain
clinic
trial
confirm
small
differ
sensit
commerci
whocnic
assay
show
greater
posit
agreement
commerci
assay
notabl
liferiv
assay
simultan
detect
three
target
intern
control
ad
conveni
detect
method
especi
sampl
addit
show
lod
valu
ident
two
commerci
assay
thu
give
advantag
observ
recent
publish
studi
lod
target
newli
develop
molecular
assay
specif
detect
viru
like
better
target
similar
result
document
previou
studi
avian
influenza
viru
demonstr
assay
detect
segment
sensit
detect
kalthoff
et
al
evalu
two
assay
analyt
sensit
use
serial
dilut
rna
viru
report
assay
assay
develop
corman
et
al
could
detect
sampl
dilut
target
neither
assay
could
detect
result
studi
indic
whocnic
assay
sensit
detect
segment
segment
consist
research
describ
result
studi
show
whocnic
assay
sensit
detect
segment
howev
commerci
assay
exhibit
ident
analyt
sensit
target
base
detect
serial
dilut
viru
sampl
confirm
find
ct
valu
detect
result
sampl
significantli
differ
target
balanc
lod
segment
commerci
kit
like
facilit
interpret
result
regular
clinic
practic
explan
differ
lod
observ
ha
na
segment
complic
possibl
na
segment
natur
fewer
copi
transcript
ha
segment
easili
degrad
clinic
specimen
contain
complex
sequenc
may
result
difficulti
primerprob
design
compar
ha
segment
howev
hypothes
requir
investig
clarif
follow
outbreak
human
infect
caus
avian
influenza
viru
mani
molecular
assay
develop
laboratori
evalu
use
clinic
specimen
howev
virusposit
clinic
sampl
use
studi
typic
number
fewer
collect
singl
locat
first
wave
diseas
studi
conduct
earli
stage
outbreak
patient
scarc
notabl
influenza
viru
rna
viru
tend
exhibit
sequenc
chang
segment
reassort
inde
genet
divers
found
among
viru
strain
initi
outbreak
diseas
one
earliest
identifi
strain
show
particularli
high
divers
comparison
virus
first
wave
epidem
occur
china
februari
human
infect
avian
influenza
viru
reemerg
octob
second
wave
epidem
sequenc
differ
also
observ
virus
collect
wave
accord
reemerg
continu
transmiss
diseas
addit
distinct
lineag
genotyp
identifi
across
provinc
epidem
period
thu
increas
genet
heterogen
viru
furthermor
report
due
dynam
reassort
local
avian
influenza
virus
virus
differ
lineag
distribut
geograph
across
provinc
instanc
guangdonghong
kongderiv
strain
observ
guangdong
provinc
observ
sequenc
divers
viru
suitabl
assay
evalu
requir
clinic
specimen
good
geograph
tempor
represent
studi
clinic
sampl
confirm
virusinfect
patient
test
use
assay
clinic
specimen
use
evalu
commerci
kit
collect
three
puruikang
liferiv
four
daan
major
epidem
region
china
zhejiang
guangdong
jiangsu
provinc
shanghai
citi
cumul
case
interv
encompass
two
epidem
wave
diseas
daan
liferiv
particularli
daan
assay
clinic
specimen
collect
infect
patient
thu
includ
half
total
confirm
case
report
date
china
success
evalu
patient
sampl
support
use
assay
clinic
laboratori
viral
load
viru
recogn
significantli
lower
throat
swab
sampl
upper
respiratori
tract
sputum
tracheal
aspir
lower
respiratori
tract
hamper
use
rapid
antigen
detect
assay
diagnos
viru
thu
clinic
sampl
differ
specimen
type
especi
throat
swab
must
use
valid
effect
assay
throat
swab
assess
present
studi
evalu
sensit
commerci
assay
detect
viru
upper
respiratori
tract
specimen
daan
puruikang
liferiv
posit
sampl
defin
refer
method
correctli
detect
commerci
assay
six
three
sampl
patient
yield
discord
result
refer
method
daan
liferiv
assay
respect
consist
previou
find
posit
sampl
detect
daan
assay
throat
swab
sampl
indic
low
copi
level
viru
upper
respiratori
tract
observ
high
sensit
commerci
assay
studi
suggest
limit
detriment
effect
throat
swab
specimen
detect
howev
previous
report
averag
ct
valu
throat
swab
sampl
approxim
close
cutoff
assay
caution
use
work
type
specimen
previous
report
inhibitori
substanc
present
clinic
sampl
substanc
may
still
activ
process
nucleic
acid
extract
interrupt
enzymebas
pcr
amplif
reduc
sensit
pcr
reaction
lead
falseneg
result
intern
control
ad
sampl
prior
nucleic
acid
extract
serv
monitor
inhibitori
factor
extract
specimen
ensur
suffici
pcr
amplif
consequ
intern
control
requir
pcrbase
assay
decreas
occurr
falseneg
result
increas
sensit
assay
detect
target
nucleic
acid
clinic
sampl
especi
presenc
complic
matrix
plasma
sputum
present
studi
found
contrast
whocnic
assay
certain
publish
assay
detect
target
separ
reaction
one
target
per
tube
evalu
commerci
duplex
triplex
assay
detect
intern
control
well
andor
one
tube
simultan
detect
internalcontrol
target
viral
rna
one
reaction
lead
better
control
falseneg
result
howev
design
improperli
intern
control
may
also
limit
abil
detect
low
amount
viral
rna
especi
comparison
simplex
assay
thu
simultan
detect
intern
control
commerci
assay
may
one
explan
present
observ
target
analyt
sensit
commerci
assay
wors
whocnic
assay
howev
given
commerci
assay
distribut
broadli
use
routin
clinic
practic
without
special
support
advantag
intern
control
reliabl
stabl
qualiti
control
exceed
disadvantag
term
potenti
loss
sensit
fact
intern
control
use
bacteriophag
incorpor
molecular
assay
use
specif
detect
avian
influenza
viru
author
us
fda
demonstr
essenti
role
intern
control
use
diagnost
assay
clinic
laboratori
addit
extern
posit
neg
control
contain
kit
underw
whole
process
detect
includ
rna
extract
monitor
fals
neg
result
caus
reagent
failur
eg
primerprob
degrad
enzym
inactiv
oper
error
well
falseposit
result
caus
reagent
andor
environment
contamin
extern
control
work
togeth
intern
control
describ
result
stringent
sustain
qualiti
control
commerci
assay
three
evalu
commerci
assay
exhibit
similar
regard
intend
use
analyt
clinic
perform
howev
certain
differ
observ
includ
type
real
time
fluoresc
pcr
techniqu
target
region
primer
probe
revers
transcript
rt
pcr
set
first
basic
principl
three
assay
name
onestep
real
time
rtpcr
howev
two
differ
type
probe
techniqu
util
taqman
hydrolysi
probe
incorpor
liferiv
daan
assay
wherea
complex
probe
use
puruikang
assay
illustr
fig
complex
probe
hybrid
quencher
closer
report
thu
latter
fluoresc
effect
inhibit
taqman
probe
thu
complex
probe
gener
exhibit
reduc
background
fluoresc
compar
tradit
taqman
hydrolysi
probe
lead
increas
analyt
sensit
find
may
explain
puruikang
assay
use
fewer
amplif
cycl
two
assay
cycl
vs
cycl
exhibit
lod
second
revers
transcript
rt
pcr
set
may
also
influenc
analyt
clinic
perform
assay
howev
differ
combin
reaction
paramet
ultim
yield
similar
perform
three
commerci
assay
exampl
increas
durat
rt
reaction
puruikang
assay
compar
liferiv
daan
assay
minut
vs
minut
like
increas
lod
potenti
increas
elimin
subsequ
reduc
extens
time
second
vs
second
second
cycl
number
cycl
vs
cycl
third
detect
region
three
commerci
assay
whocnic
method
locat
ha
na
gene
avian
influenza
viru
found
less
differ
although
posit
target
region
gene
divers
certain
consensu
note
among
commerci
assay
may
account
equal
lod
observ
among
assay
three
commerci
assay
target
region
around
posit
ha
gene
two
commerci
assay
daan
puruikang
target
region
around
nt
na
gene
whocnic
method
target
region
beyond
consensu
posit
commerci
assay
differ
target
region
whocnic
commerci
assay
may
explain
enhanc
sensit
whocnic
method
detect
viral
segment
studi
two
limit
recent
studi
found
sever
molecular
assay
recent
develop
detect
avian
influenza
viru
also
display
crossreact
avian
anim
influenza
virus
current
humaninfect
viru
influenza
virus
includ
qualitycontrol
panel
clinic
specimen
thu
studi
exclud
possibl
commerci
assay
crossreact
anim
influenza
virus
investig
futur
studi
howev
result
commerci
assay
interpret
avian
influenza
viru
rnaposit
posit
intend
use
assay
test
anim
sampl
influenza
virus
undetermin
crossreact
may
hamper
applic
assay
current
patient
sampl
anoth
limit
studi
stabil
human
materi
present
sampl
qualitycontrol
panel
thu
prevent
us
evalu
efficaci
endogen
intern
control
puruikang
assay
conclus
studi
first
establish
panel
qualitycontrol
materi
use
conduct
analyt
evalu
commerci
kit
addit
clinic
perform
kit
valid
use
larg
number
patient
specimen
divers
characterist
good
repres
therefor
studi
provid
comprehens
evid
regard
perform
commerci
diagnost
assay
specif
detect
avian
influenza
viru
high
perform
commerci
diagnost
assay
warrant
applic
clinic
set
believ
studi
benefit
prepared
reemerg
even
potenti
pandem
viru
demonstr
detect
efficaci
commerci
assay
may
facilit
qualiti
improv
assay
although
establish
urgent
basi
qualitycontrol
panel
use
present
studi
indispens
qualiti
evalu
similar
product
acquir
upon
request
nation
institut
food
drug
control
china
